Innovative Study on Immunocal and Children Diagnosed with ASD
In Montreal, Canada, it has been announced that Nova Southern University (NSU) in Florida is conducting groundbreaking research to evaluate the impacts of Immunocal on the behavior of children with Autism Spectrum Disorders (ASD). Immunocal, Immunotec‘s flagship product, is a whey protein isolate.
Potential for Improvement in the Behavior of Children with Autism
The primary goal of this two-year study is to determine whether children with autism experience improvement in behavior after consuming the cysteine-rich proteins in Immunocal over a 90-day observation period. The results could translate into a higher quality of life for both children and their families.
Research Led by Ana María Castejon and her Team
The principal investigator of this project, carried out in collaboration between NSU and Immunotec, is Ana María Castejon, PhD., associate professor in the College of Pharmacy. Together with her research team, they are excited about the possible implications of this study. Castejon mentioned that current approaches to autism have been widely disseminated but lack evidence about their effectiveness.
Immunotec and NSU Perspective on Research
Immunotec President Stuart MacMillan expressed his support for this research, highlighting the company’s ongoing collaboration with renowned researchers. For his part, Dr. Gary S. Margules, NSU Vice President of Research and Technology Transfer, praises the initiative as an outstanding example of multidisciplinary clinical research.
Importance of Research in Autism
According to the Centers for Disease Control (CDC) and Health Canada, approximately 1 in 150 children worldwide are affected by autism spectrum disorders, a number that is constantly increasing. Traditional treatment focuses on special education, behavioral therapy, and other medical approaches. This collaboration between Immunotec and NSU marks a significant advance in autism research.
